Literature DB >> 7362377

Meperidine for the treatment of shaking chills and fever.

L C Burks, J Aisner, C L Fortner, P H Wiernik.   

Abstract

Meperidine hydrochloride was evaluated in a prospectively randomized double-blind study for its effectiveness in stopping shaking chills occurring with amphotericin B infusions. Seven patients were randomized on multiple occasions for a total of 19 reactions. In the meperidine group, nine of nine reactions stopped within 30 minutes of the administration of meperidine, with a mean cessation time of 10.8 minutes. The placebo group had a mean time of 37.4 minutes to cessation of reactions with three of ten reactions subsiding spontaneously. The mean dose of meperidine hydrochloride for cessation of reaction was 45 mg. The comparisons between meperidine and placebo for cessation of reaction within 30 minutes and the mean time to cessation of reaction were significantly different. Side effects with meperidine were minimal and less severe than the shaking chills and fever seen with amphotericin B infusions. Meperidine can eliminate these reactions more effectively and more rapidly than simply discontinuing the amphotericin B.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7362377

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  10 in total

Review 1.  Adverse drug reactions to systemic antifungals. Prevention and management.

Authors:  J R Perfect; M H Lindsay; R H Drew
Journal:  Drug Saf       Date:  1992 Sep-Oct       Impact factor: 5.606

Review 2.  Physiology and clinical relevance of induced hypothermia.

Authors:  Anthony G Doufas; Daniel I Sessler
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

3.  Intravenous meperidine for control of shivering during caesarean section under epidural anaesthesia.

Authors:  W F Casey; C E Smith; J M Katz; K O'Loughlin; S K Weeks
Journal:  Can J Anaesth       Date:  1988-03       Impact factor: 5.063

Review 4.  Hypothermia after acute ischemic stroke.

Authors:  Thomas M Hemmen; Patrick D Lyden
Journal:  J Neurotrauma       Date:  2009-03       Impact factor: 5.269

5.  Problems in antifungal chemotherapy.

Authors:  D A Stevens
Journal:  Infection       Date:  1987 Mar-Apr       Impact factor: 3.553

Review 6.  Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.

Authors:  C A Lyman; T J Walsh
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

7.  Meperidine to control shivering associated with platelet transfusion reaction.

Authors:  M Friedlander; W H Noble
Journal:  Can J Anaesth       Date:  1989-07       Impact factor: 5.063

Review 8.  Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections.

Authors:  Francelise B Cavassin; João Luiz Baú-Carneiro; Rogério R Vilas-Boas; Flávio Queiroz-Telles
Journal:  Infect Dis Ther       Date:  2021-02-01

9.  Educational Case: Febrile Nonhemolytic Transfusion Reaction.

Authors:  Aaron D Shmookler; Melina B Flanagan
Journal:  Acad Pathol       Date:  2020-07-14

10.  Rigor prophylaxis in stage IV melanoma and renal cell carcinoma patients treated with high dose IL-2.

Authors:  Brian Khong; Benjamin O Lawson; Junjie Ma; Cheryl McGovern; Joan K Van Atta; Abhijit Ray; Hung T Khong
Journal:  BMC Cancer       Date:  2018-10-20       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.